Seeking Alpha

Dendreon (DNDN -1.3%) agrees to pay $40M to settle a class-action investor lawsuit that alleges...

Dendreon (DNDN -1.3%) agrees to pay $40M to settle a class-action investor lawsuit that alleges that the company made "false or misleading statements," particularly about its Provenge cancer drug. Dendreon continues to deny that it made such statements, and says its insurers will pay $38M of the settlement. (PR)
Comments (1)
  • Lawrence Marc-Aurele
    , contributor
    Comments (106) | Send Message
     
    What misleading statements is Dendreon alledged to have made?
    18 Mar 2013, 03:22 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|